Clinical Trial Update: A Study of MabThera (Rituximab) Addition to Regularly Prescribed Chemotherapy in Patients With Untreated Mantle Cell Lymphoma. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Rituximab added to standard chemotherapy in untreated mantle cell lymphoma was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• MabThera (Rituximab) (rituximab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Diffuse Large B-Cell Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2016-08-29